In 2021, the combination of TRNT using radiolabeled alkylphosphocholine (APC) analog [90Y]Y-NM600 and ICI was shown to enhance the CD8+ immune response against T-cell non-Hodgkin lymphoma showed strong therapeutic effects, with 45 to 66% of mice exhibiting complete tumor response and developing tumor-specific T cell memory compared to none with either treatment alone [195]. This evidence concerns the gene CD8A and neoplasm.